In 2025, Jiangsu Hengrui Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
However, Jiangsu Hengrui Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 54,874.45a | 8,516.6a | 4,898a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 270,564.48a | 249,380.64a | 203,382.08a | |
Total Scope 3 | 756,662.33a | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 12.1459a | 2.221a | 1.5254a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Jiangsu Hengrui Pharmaceuticals amounted to 325,438.93 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Jiangsu Hengrui Pharmaceuticals increased by 26.19%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Jiangsu Hengrui Pharmaceuticals were 54,874.45 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, Jiangsu Hengrui Pharmaceuticals's Scope 1 emissions have increased by 520.91%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2024), Jiangsu Hengrui Pharmaceuticals's Scope 1 emissions increased by 544.32%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, Jiangsu Hengrui Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 270,564.48 tCO₂e without specifying the calculation method.a
Since 2021, Jiangsu Hengrui Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 15.02%, reflecting a rising long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2024), Jiangsu Hengrui Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Jiangsu Hengrui Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, Jiangsu Hengrui Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.a
In 2025, Jiangsu Hengrui Pharmaceuticals reported 756,662.33 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Jiangsu Hengrui Pharmaceuticals includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Jiangsu Hengrui Pharmaceuticals reported total Scope 3 emissions of 756,662.33 metric tons of CO₂ equivalent (tCO₂e).a
In 2025, Jiangsu Hengrui Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 54,874.45 tCO₂e and total revenues of USD 4,518 millions. This translates into an emissions intensity of 12.15 tCO₂e per millions USD.a
In 2025, Jiangsu Hengrui Pharmaceuticals reported a Scope 1 emissions intensity of 12.15 tCO₂e per millions USD. Compared to the peer group median of 25.37, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Jiangsu Hengrui Pharmaceuticals ranked 8 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Jiangsu Hengrui Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2025, Jiangsu Hengrui Pharmaceuticals reported a total carbon footprint of 1,082,101.26 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 319.59% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Jiangsu Hengrui Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 69.93% of the company's total carbon footprint, followed by Scope 2 emissions at 25%.a